Yoder Mervin C
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, 1044 W. Walnut Street, R4-402E, Indianapolis 46202, USA.
Oncogene. 2004 Sep 20;23(43):7161-3. doi: 10.1038/sj.onc.1207931.
The precise temporal and spatial emergence of hematopoietic stem cells (HSC) in the murine embryo has been somewhat controversial largely due to differences in the assays utilized to demonstrate HSC repopulating ability. One strategy is to determine where and when one can first detect HSC that engraft upon transplantation into lethally irradiated adult mice. However, knowing that the primary sites and patterns of hematopoiesis change during ontogeny, an alternative strategy is to select transplantation models where the recipient subjects more closely mirror the stage of development of the donor cells. In this regard, perhaps the most relevant assay to determine the presence of HSC activity in the early embryo is to transplant the donor cells in utero into recipient embryos. Other recipient models that may permit engraftment of embryonic cells include the use of submyeloablated or genetically HSC deficient newborn mice. Additional informative strategies have included co-culturing embryonic tissues that appear to lack HSC activity, with stromal cells derived from different developmental sites of hematopoiesis to induce HSC emergence, followed by transplantation as a means to determine which embryonic tissues possess HSC potential. This review will highlight some of the various transplantation assays used to identify HSC from embryonic tissues.
由于用于证明造血干细胞(HSC)重建能力的检测方法存在差异,小鼠胚胎中造血干细胞精确的时空出现情况在一定程度上存在争议。一种策略是确定在何处以及何时能够首次检测到移植到经致死性照射的成年小鼠体内后能够植入的造血干细胞。然而,鉴于造血的主要部位和模式在个体发育过程中会发生变化,另一种策略是选择受体对象更能反映供体细胞发育阶段的移植模型。在这方面,用于确定早期胚胎中造血干细胞活性存在的最相关检测方法可能是将供体细胞在子宫内移植到受体胚胎中。其他可能允许胚胎细胞植入的受体模型包括使用亚骨髓消融或基因造血干细胞缺陷的新生小鼠。其他有参考价值的策略包括将似乎缺乏造血干细胞活性的胚胎组织与源自造血不同发育部位的基质细胞共同培养,以诱导造血干细胞出现,然后进行移植,以此来确定哪些胚胎组织具有造血干细胞潜能。本综述将重点介绍一些用于从胚胎组织中鉴定造血干细胞的不同移植检测方法。